



Zelboraf® (vemurafenib) – New warning

- The [FDA approved](#) an update to the *Warnings and Precautions* section of the [Zelboraf \(vemurafenib\)](#) drug label regarding Dupuytren's contracture and plantar fascial fibromatosis.
- Zelboraf is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
 - Zelboraf is not indicated for treatment of patients with wild-type BRAF melanoma.
- Dupuytren's contracture and plantar fascial fibromatosis have been reported with Zelboraf. The majority of cases were mild to moderate, but severe, disabling cases of Dupuytren's contracture have also been reported.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.